At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Tivantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Tivantinib for Estrogen Receptor Negative and 5 related conditions. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEstrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedApr 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedApr 11, 2012
Enrollment StartMar 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.2 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Tivantinibdrug
Given PO